Natco Pharma signs pact with Eli Lilly for Baricitinib

Withdraws application seeking Compulsory License against Lilly for the COVID-19 drug

May 17, 2021 11:22 pm | Updated 11:22 pm IST - HYDERABAD

Natco Pharma has signed a royalty-free, non-exclusive, voluntary licensing agreement with pharma major Eli Lilly for the manufacture and commercialisation of Baricitinib, a drug indicated for the treatment of COVID-19.

In line with the agreement, Natco has withdrawn the application filed with the Indian Patent Office seeking Compulsory License against Lilly for Baricitinib for COVID-19 in India, the company said on Monday.

Earlier this month, Natco had received emergency use authorisation for Baricitinib tablets from the Central Drugs Standard Control Organisation (CDSCO). The drug is for use, in combination with Remdesivir, in treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Following the EUA, it had also launched the product.

Cipla, Sun, Lupin, Dr. Reddy’s Laboratories, Torrent and MSN Labs are other companies with whom Eli Lilly had recently entered into a licensing agreement for Baricitinib.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.